Suppr超能文献

miR24-2 通过增强酪氨酸激酶Src 的表观遗传促进人肝癌干细胞的恶性进展。

miR24-2 Promotes Malignant Progression of Human Liver Cancer Stem Cells by Enhancing Tyrosine Kinase Src Epigenetically.

机构信息

Shanghai Putuo District People's Hospital, School of Life Science and Technology, Tongji University, Shanghai 200092, China.

School of Medicine, Tongji University, Shanghai 200092, China.

出版信息

Mol Ther. 2020 Feb 5;28(2):572-586. doi: 10.1016/j.ymthe.2019.10.015. Epub 2019 Oct 24.

Abstract

MicroRNA24-2 (miR24-2) is associated with human tumorigenesis; however, its molecular mechanisms are poorly understood. Herein, our findings demonstrate that miR24-2 promotes the proliferation ability in vitro and the tumorigenic ability in vivo in human liver cancer stem cells (hLCSCs). Mechanically, the miR24-2 targets for 3' UTR (2,627-2,648) of protein arginine methyltransferase 7 (PRMT7) inhibit the translational ability of prmt7 gene. Moreover, miR24-2 inhibits the di-/tri-methylation of histone H4 arginine 3 by reducing PRMT7 and then promotes the expression of Nanog via long noncoding RNA HULC. Notably, miR24-2 inhibits histone deacetylase HDAC3 through miR675, which promotes the acetylation of histone H4 at lysine 16. Subsequently, miR24-2 enhances the interaction between LC3 and ATG4 dependent on PI3K and triggers cellular autophagy. Strikingly, miR24-2 inhibits the degradation of pyruvate kinase M1 via autophagosome-P62 in hLCSCs. Furthermore, miR24-2 enhances the activity of Src by promoting the binding of PKM1 to the Src promoter regions in hLCSCs. In particular, our results also indicate that src gene determines the oncogenic functions of miR24-2. These results provided a valuable theoretical basis for the discovery of liver cancer therapeutic targets and diagnosis markers based on miR24-2.

摘要

miR24-2(miR24-2)与人类肿瘤发生有关;然而,其分子机制尚不清楚。在此,我们的研究结果表明,miR24-2 可增强人肝癌干细胞(hLCSC)体外的增殖能力和体内的致瘤能力。从机制上讲,miR24-2 的靶标是蛋白质精氨酸甲基转移酶 7(PRMT7)的 3'UTR(2,627-2,648),抑制 prmt7 基因的翻译能力。此外,miR24-2 通过减少 PRMT7 抑制组蛋白 H4 精氨酸 3 的二甲基化/三甲基化,从而促进长链非编码 RNA HULC 表达 Nanog。值得注意的是,miR24-2 通过 miR675 抑制组蛋白去乙酰化酶 HDAC3,促进组蛋白 H4 赖氨酸 16 的乙酰化。随后,miR24-2 通过 PI3K 增强 LC3 和 ATG4 之间的相互作用,触发细胞自噬。引人注目的是,miR24-2 通过自噬体-P62 抑制丙酮酸激酶 M1 在 hLCSC 中的降解。此外,miR24-2 通过促进 PKM1 与 hLCSC 中 Src 启动子区域的结合,增强 Src 的活性。特别是,我们的结果还表明,src 基因决定了 miR24-2 的致癌功能。这些结果为基于 miR24-2 发现肝癌治疗靶点和诊断标志物提供了有价值的理论基础。

相似文献

引用本文的文献

4
Autophagy and cancer therapy.自噬与癌症治疗。
Cancer Lett. 2024 Nov 28;605:217285. doi: 10.1016/j.canlet.2024.217285. Epub 2024 Oct 10.
6
Cancer metastases: Tailoring the targets.癌症转移:靶向治疗
Heliyon. 2024 Aug 2;10(15):e35369. doi: 10.1016/j.heliyon.2024.e35369. eCollection 2024 Aug 15.
8
Elucidation of how the Mir-23-27-24 cluster regulates development and aging.阐明 Mir-23-27-24 簇如何调节发育和衰老。
Exp Mol Med. 2024 Jun;56(6):1263-1271. doi: 10.1038/s12276-024-01266-3. Epub 2024 Jun 14.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验